The early (yet-to-be-published) results of a University of Chicago study of remdesivir to treat coronavirus are promising.
esearchers at University of Chicago reported promising results from a small study of remdesivir in treating people with COVID-19.
The findings were not published in a peer-reviewed journal, but revealed in an internal video discussion of the drug trial among University of Chicago faculty that wasThe study included 125 people with COVID-19, all of whom were treated with the remdesivir, which is not currently approved in the U.S. for treating any disease. Of the 125 patients in the Chicago study, 113 had severe disease, meaning they had difficulty breathing.
Remdesivir works by mimicking one of the genetic elements that the COVID-19 virus, known as SARS-CoV-2, uses to make more copies of itself. The substitute blocks the virus from copying its genome, jamming up the viral copy machine. The drug was initially developed by Gilead as a possible treatment for Ebola, but when early trials against that disease were disappointing, the company put further development on hold. However, previous lab studies showed that remdesivir actually hadlike SARS and MERS than against Ebola, so when COVID-19, also caused by a coronavirus, emerged, scientists aware of the lab data began using the drug to treat the new disease.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Remdesivir eases covid-19 symptoms in monkeys in 12 hours, small preliminary study showsThere is currently no specific treatment for COVID-19.
Read more »
Gilead increases enrollment target for remdesivir trial in COVID-19 patientsGilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise.
Read more »
Turns Out, Ellen's a Pretty Shitty BossHer crew is 'outraged' at their treatment during COVID-19.
Read more »
UK shares join global rally, Rio Tinto surges on upbeat resultsBritain's stock markets jumped on Friday as investors cheered plans for gradual restarting of the U.S. economy and encouraging data on possible treatment for the COVID-19 disease.
Read more »
Gilead drug produced ‘rapid’ recovery in coronavirus patients, report saysGilead stock pops in after-hours trading; its experimental drug remdesivir is considered a front-runner in the race to develop a treatment for COVID-19 infections.
Read more »
No evidence yet for effective COVID-19 treatments, review showsAlthough would-be COVID-19 therapies like the malaria drug hydroxychloroquine and the failed Ebola drug remdesivir have drummed up excitement as potentially life-saving treatments, a comprehensive review of available data finds that it's still too early to tell. The review, published in JAMA on
Read more »